Clinical trial Recruiting at 3 sites Interventional

Nasal high-flow therapy for COPD exacerbations

Official title: Nasal High-Flow Therapy to Treat COPD Exacerbations: a Matter of Monitoring and Controlling Settings?

Run by University Medical Center Groningen · NCT03564236 · Data updated 2026-11-12

This study is testing if nasal high-flow therapy can help hospitalized patients with COPD recover better from flare-ups compared to standard care.

Quick facts

Study typeInterventional
SexAll
Enrollment136 (estimated)
SponsorUniversity Medical Center Groningen
Academic / other
Locations3 sites (Arnhem and 2 other locations)
StatusRecruiting
StartedOctober 1, 2018
Main results expectedOctober 31, 2025
Study endsDecember 30, 2025
Registry record updatedDecember 5, 2024
Trial IDNCT03564236 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are hospitalized patients with COPD (GOLD stage II to IV) experiencing exacerbations and showing signs of compensated respiratory failure.

Probably not a fit

Patients with stable COPD or those not experiencing exacerbations may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy of nasal high-flow therapy (nHFT) in enhancing recovery from COPD exacerbations in hospitalized patients. It is a multicenter, randomized controlled trial comparing nHFT to standard care, aiming to include 136 patients. The study will also explore the underlying mechanisms of nHFT through neuromechanical and anatomical investigations. By understanding how nHFT works, the study seeks to optimize its application for COPD patients experiencing exacerbations.

Why it matters

Potential benefit: If successful, this therapy could significantly improve recovery times and quality of life for patients suffering from COPD exacerbations.

How similar studies have gone: Preliminary evidence suggests nHFT may be effective in stable COPD patients, but this approach in exacerbations is novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients have to fulfil all of the following inclusion criteria:

* History of COPD Global Initiative of Obstructive Lung Diseases (GOLD) stage II to IV (FEV1\< 80% of predicted with an FEV1/forced vital capacity (FVC) ratio \<70), with a history of at least 10 pack years smoking.
* Being admitted to the hospital with a COPD exacerbation
* Signs of compensated respiratory failure (hypercapnia (partial arterial carbon dioxide pressure (PaCO2) ≥ 6.0 kPa and/or hypoxemia (partial arterial oxygen pressure (PaO2) ≤ 8.0 kPa at room air), with pH \> 7.34
* At least 2 COPD exacerbations in the year prior to the index hospital admission (exacerbation defined as worsening of pulmonary symptoms requiring oral steroids and/or antibiotics and/or hospital admission)
* Written informed consent is obtained

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* No lung function data available
* The presence of another acute condition (e.g. pneumonia, acute congestive heart failure, pulmonary embolus) explaining or significantly contributing to the index admission
* Inability to comply with the tests
* The presence of another chronic lung disease (e.g. asthma, restrictive lung disease).

Where it's running

  • Rijnstate Hospital
    Arnhem, Netherlands
    Recruiting
  • Albert Schweizer ziekenhuis
    Dordrecht, Netherlands
    Recruiting
  • University Medical Center Groningen
    Groningen, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Early detection of COPD flares with a home monitoring device

    A home-monitoring device called RespirAI is being tested to see if it can alert adults with COPD about coming flare-ups before they happen.

    Recruiting RespirAI US Inc · Omaha, Nebraska · NCT07554352

  • High-intensity resistance training after a COPD exacerbation

    This project tests whether a short program of high-load, low-repetition leg-strength training helps people recovering from a COPD flare rebuild strength and exercise tolerance with less breathlessness than standard endurance exercise.

    Recruiting Istituti Clinici Scientifici Maugeri SpA · Lumezzane, Brescia · NCT07302425

  • Improving oral care to prevent pneumonia in COPD patients in the ICU

    This study is testing if better oral care can help prevent pneumonia in COPD patients who are in the ICU.

    Recruiting Assiut University · Asyut · NCT06691399

  • Support for COPD patients after hospital discharge

    This study tests whether giving COPD patients special rescue packs with medication and a management plan after they leave the hospital can help them stay healthier and avoid going back to the hospital.

    Recruiting at 10 sites Phase 3 Guy's and St Thomas' NHS Foundation Trust · Barnsley and 33 other locations · NCT06347536

  • Observing patients with severe COPD exacerbations in the ICU

    This study looks at patients with severe COPD flare-ups in the ICU to learn more about their health, treatments, and chances of recovery.

    Recruiting at 4 sites Versailles Hospital · Grenoble and 3 other locations · NCT06257329

  • Effects of CPAP on COPD and Sleep Apnea Overlap Syndrome

    This study is testing if using a CPAP machine can help people with both COPD and sleep apnea feel better and reduce health problems over a year.

    Recruiting at 15 sites University Hospital, Angers · Angers and 14 other locations · NCT05958563

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.